Compound details
N-Acetylmuramate
| Compound ID | CDAMM00110 |
|---|---|
| Common name | N-Acetylmuramate | IUPAC name | (2R)-2-[(3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoic acid |
| Molecular formula | C11H19NO8 |
| Retention time | 60.82 |
|---|---|
| Adduct | [M+H]+ |
| Actual mz | 294.117 | Theoretical mz | 294.118 |
| Error | 2.85 |
| Ionizaton mode | Positive |
| Instrument type | LC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60 |
| Score | 6.5595 |
| Inchi key | MNLRQHMNZILYPY-FTNICRTINA-N |
|---|---|
| Smiles | CC(C(=O)O)OC1C(C(OC(C1O)CO)O)NC(=O)C |
| Superclass | Organic oxygen compounds |
| Class | Organooxygen compounds |
| Uniprot ID | Gene name | Target name | TTD_ID | Prediction source |
|---|---|---|---|---|
| P16278 | GLB1 | Beta-galactosidase (by homology) | T73134 | SEA |
| Q9BZP6 | CHIA | Acidic mammalian chitinase (by homology) | T51597 | SEA |
| P32320 | CDA | Cytidine deaminase (by homology) | T79027 | SEA |
| P15692 | VEGFA | Vascular endothelial growth factor A | T20761 | SEA |
| P05230 | FGF1 | Acidic fibroblast growth factor | T18639 | SEA |
| P09038 | FGF2 | Basic fibroblast growth factor | T31621 | SEA |
| P52789 | HK2 | Hexokinase type II | T96685 | SEA |
| P16109 | SELP | P-selectin | T10965 | SEA |
| P17931 | LGALS3 | Galectin-3 | T72038 | SEA |
| P04746 | AMY2A | Pancreatic alpha-amylase | T86918 | SEA |
| P14679 | TYR | Tyrosinase | T97035 | SEA |
| P20916 | MAG | Myelin-associated glycoprotein (by homology) | T95286 | SEA |
| P09382 | LGALS1 | Galectin-1 | T09544 | SEA |
| Q07108 | CD69 | Early activation antigen CD69 | T48780 | SEA |
| TTD_ID | Disease_ID | Disease name | ICD_11 | Uniprot ID | Gene names |
|---|---|---|---|---|---|
| T73134 | DI0242 | Lysosomal disease | [ICD-11: 5C56] | P16278 | GLB1 |
| T79027 | DI0391 | Solid tumour/cancer | [ICD-11: 2A00-2F9Z] | P32320 | CDA |
| T20761 | DI0095 | Colorectal cancer | [ICD-11: 2B91] | P15692 | VEGFA |
| T20761 | DI0365 | Retinopathy | [ICD-11: 9B71] | P15692 | VEGFA |
| T20761 | DI0430 | Vascular system developmental anomaly | [ICD-11: LA90] | P15692 | VEGFA |
| T18639 | DI0081 | Chronic arterial occlusive disease | [ICD-11: BD4Z] | P05230 | FGF1 |
| T18639 | DI0102 | Coronary atherosclerosis | [ICD-11: BA52] | P05230 | FGF1 |
| T31621 | DI0005 | Acne vulgaris | [ICD-11: ED80] | P09038 | FGF2 |
| T96685 | DI0133 | Epidermal dysplasias | [ICD-11: EK90] | P52789 | HK2 |
| T10965 | DI0088 | Circulatory system disease | [ICD-11: BE2Z] | P16109 | SELP |
| T10965 | DI0381 | Sickle-cell disorder | [ICD-11: 3A51] | P16109 | SELP |
| T72038 | DI0190 | Hypertension | [ICD-11: BA00-BA04] | P17931 | LGALS3 |
| T72038 | DI0199 | Idiopathic interstitial pneumonitis | [ICD-11: CB03] | P17931 | LGALS3 |
| T72038 | DI0252 | Melanoma | [ICD-11: 2C30] | P17931 | LGALS3 |
| T72038 | DI0302 | Non-alcoholic fatty liver disease | [ICD-11: DB92] | P17931 | LGALS3 |
| T72038 | DI0351 | Psoriasis | [ICD-11: EA90] | P17931 | LGALS3 |
| T86918 | DI0110 | Cystic fibrosis | [ICD-11: CA25] | P04746 | AMY2A |
| T86918 | DI0328 | Pancreatic malfunction | [ICD-11: DC30-DC3Z] | P04746 | AMY2A |
| T97035 | DI0007 | Acquired hypermelanosis | [ICD-11: ED60] | P14679 | TYR |
| T97035 | DI0008 | Acquired hypomelanotic disorder | [ICD-11: ED63] | P14679 | TYR |
| T95286 | DI0219 | Ischaemic/haemorrhagic stroke | [ICD-11: 8B20] | P20916 | MAG |